Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4sCAR-DLL3 CAR-T Therapy Targeting Brain Tumors
NCT07180927Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- May 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of 4SCAR-DLL3 T cells in glioblastoma (GBM), diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
4SCAR-DLL3 T cells
03
Conditions
glioblastoma (GBM)diffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT07180927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07180927.